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BACKGROUND: In recent years, there has been a
growing interest in reducing the overuse of
healthcare services. However, little is known about
how patients conceptualize the benefits and harms
of overused screening tests or how patients make
decisions regarding these tests.
OBJECTIVE: To determine how patients think about the
harms and benefits of overused screening tests and how
they consider these and other factors when making
decisions.
DESIGN: Semi-structured, qualitative interviews.
PARTICIPANTS: The study comprised 50 patients,
ages 50–84, who had previously received or not re-
ceived any of four overused screening services: 1)
prostate cancer screening (men ages 50–69), 2) colon
cancer screening (men and women ages 76–85), 3)
osteoporosis screening (low-risk women ages 50–64),
or 4) cardiovascular disease screening (low-risk men
and women ages 50–85).
APPROACH: We conducted a thematic analysis, using a
hybrid inductive-deductive approach. Two independent
coders analyzed interview transcriptions to identify
themes and exemplifying quotes.
KEY RESULTS: Many patients could not name a
harm of screening. When they did name harms, pa-
tients often focused on only the harms of the screen-
ing test itself and rarely mentioned harms further
along the screening cascade (e.g., from follow-up
testing and treatment). In contrast, patients could
easily name benefits of screening, although many
seemed to misunderstand or overestimate the mag-
nitude of the benefits. Furthermore, patients de-
scribed many additional factors they considered
when making screening decisions, including their
clinicians’ recommendations, their age, family or
friends’ experiences with disease, and insurance
coverage.
CONCLUSIONS: This study highlights the need to help
adults recognize and understand the benefits and harms
of screening and make appropriate decisions about
overused screening tests.
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Patient education; Preventive care.
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INTRODUCTION
In recent years, there has been a growing interest in reducing
the overuse of healthcare services1–3. Overuse, defined as Bthe
use of healthcare services for which the harms outweigh the
benefits,^ extends across the spectrum of screening, diagnostic
testing, and treatment, contributing at least $158 billion of
annual unnecessary healthcare costs1,3,4, and resulting in phys-
ical, psychological, and financial harms to patients and missed
opportunities to provide more beneficial care5,6.
In response to these problems, professional societies and
national experts are calling for action. As part of the Choosing
Wisely Campaign, 62 organizations have created BTop 5^ lists
of tests and treatments that providers and patients should use
less often7–9, thus improving the quality and reducing the cost
of care10. Additionally, the United States Preventive Services
Task Force (USPSTF) has identified Bavoiding the unintended
harms of medical procedures and testing in older adults^ as a
priority in their annual report on evidence gaps in preventive
services11. Almost one-quarter of adult preventive services
reviewed and graded by the USPSTF received a grade of D,
indicating that the harms of these services outweigh the ben-
efits12. Others received a C grade, indicating little benefit on a
population level, and raising concerns about overuse for at
least some individuals12.
Despite the growing interest in overuse, little is known
about how to best reduce overuse of services13. Because
patients are often unrealistically enthusiastic about screen-
ing14, a key component of any reduction strategy should be
understanding patients’ perspectives, needs, and concerns spe-
cifically about overused services. To date, however, few stud-
ies have explored whether and how patients generally think
about the harms and benefits of overused screening tests, or
how patients use other factors to come to a decision about
whether to receive these tests15.
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Our study aimed to understand patients’ perceptions of the
harms and benefits of screening and the additional factors they




We conducted semi-structured, one-on-one in-person inter-
views as part of a mixed-methods study that also included a
randomized controlled trial (RCT) comparing the effective-
ness of four communication strategies to reduce overuse of
potentially harmful screening services. This paper describes
only the qualitative interviews. The institutional review boards
of the University of North Carolina, Chapel Hill, and Duke
University Health System approved the study.
Participants
We recruited 50 patients from four Duke Primary Care Re-
search Consortium (PCRC) practices (two internal medicine,
two family medicine) in central North Carolina. Patients were
50 to 85 years of age and were eligible to receive information
about at least one of four screening services based on their age
and health factors (Table 1). Two screening services received
D grades from the USPSTF, indicating net harm at the popu-
lation level12: (1) prostate cancer screening in men ages 50–
69, and 2) cardiovascular disease screening in low-risk men
and women ages 50–85. Two others received C grades from
the USPSTF, indicating little net benefit at the population
level16: (3) colon cancer screening in men and women ages
76–85, and (4) osteoporosis screening in low-risk women ages
50–64. Of note, osteoporosis screening in women ages 50–64
received a C grade in 2002, but did not receive a grade when
recommendations were revised in 201117,18.
We excluded patients with no phone number, who did not
speak English, or who met any of the following criteria: psy-
chosis, alcohol or substance abuse within the last two years,
dementia or other severe cognitive dysfunction, metastatic can-
cer, cirrhosis, kidney failure requiring dialysis, chronic obstruc-
tive pulmonary disease (COPD) or congestive heart failure
requiring oxygen, or any other illness for which life expectancy
was less than two years. We purposely sampled to include
patients in all four screening service groups and patients who
were either previously screened with at least one of the four
tests of interest or who were eligible but had not been screened.
Our aimwas to select information-rich cases that would provide
a broad spectrum of experiences and perceptions.
Interview Content and Procedures
After identifying eligible patients through medical records,
Duke PCRC staff mailed letters to eligible patients and follow-
ed up with up to three telephone calls. For patients who agreed
to participate, we conducted interviews during a routine clinic
visit or a unique visit for the purpose of this study. Patients
provided written informed consent prior to participating
in the interviews.
Two interviewers with extensive qualitative research expe-
rience (co-authors AS and MV) conducted interviews in pri-
vate rooms at study practices. To ensure consistency, they
reviewed the interview guide together prior to starting inter-
views. After three interviews, the two interviewers met with
co-author SS to review the transcripts for interview consisten-
cy and to assess the need for additional probing questions.
During study visits and prior to any questioning, the inter-
viewers reviewed with patients a handout that provided defi-
nitions of screening, benefits, and harms. Interviews assessed
patients’ experiences with screening and their general knowl-
edge of the harms and benefits of screening (Appendix 1).
Patients then read one-page evidence-based information sheets
on the screening services pertinent to them. Information on
these sheets was derived from USPSTF reports and best
evidence by a panel of experts from UNC’s Research Center
for Excellence in Clinical Preventive Services17–46. Each in-
formation sheet included a description of the pertinent condi-
tion (including its incidence and mortality rates), description
of the screening test, and the quantitative benefits and harms of
screening for that condition (Appendix 2). After reviewing the
information sheet, patients answered additional questions
about their intent to be screened for that particular condition
and the factors they considered in deciding whether to be
screened. The mean length of the interviews was 27 minutes
(range, 15–55 minutes).
Data Analysis
Each interview was digitally recorded and transcribed verba-
tim for analysis. Analysis involved three steps: immersion
Table 1 Study Inclusion Criteria for Patients
Eligible for Prostate cancer screening (prostate-specific antigen test)
Men
50-69 years old
No history of prostate cancer
Eligible for Osteoporosis screening (bone density test)
Women
50-64 years old
Body mass index of 18 or higher
No personal history of fracture
No family history of osteoporosis
No current use of prednisone (> 30 consecutive days)
Alcohol use < 3 drinks/day
No current smoking
Eligible for Colon cancer screening (colonoscopy, sigmoidoscopy, or
fecal occult blood test)
Men or women
76-85 years old
No history of colorectal cancer
No history of adenomatous polyps, gastrointestinal bleeding, or
symptoms prompting testing




No history of cardiovascular disease
Low risk (≤ 5 %) for future coronary heart disease events according to
Framingham calculator
1619Sutkowi-Hemstreet et al.: Benefits and harms of overused screening testsJGIM
(reading and rereading transcripts to become immersed in the
data), coding (assigning descriptive codes to appropriate seg-
ments of text), and thematic analysis (identification of salient
themes related to patient perceptions of screening based on
content and interpretative analysis)
47,48. We imported inter-
view transcripts into ATLAS.ti (v.6.2), a qualitative data man-
agement program. Two independent coders (AS and MV)
created a codebook with operational definitions using inter-
view guide questions and the Harris et al. taxonomy of harms
so that we could later triangulate our findings with their
taxonomy5. The coders worked together to reach consensus
on codes and operational definitions and to set a priori rules for
coding. The two coders then independently read and coded all
transcripts using both deductive and inductive coding tech-
niques to assign codes to appropriate segments of text. They
used a constant comparison technique such that new codes
were iteratively added to the codebook, and codes that were
not used upon completion of coding were removed47. All
transcripts were double-coded, with discrepancies resolved
through discussion of coding decisions and referral to the
codebook and a priori coding rules. Three members of the
research team (AS, MV, and SS) then read through text asso-
ciated with specific codes and met weekly to discuss, refine,
and finalize emergent themes.
RESULTS
We contacted 185 patients who met inclusion criteria
and were eligible for participation in interviews. Sixty-
five patients agreed to participate. Of these patients, 14
did not show up for their scheduled study visits, and
one was subsequently deemed ineligible. Thus, 50 pa-
tients were enrolled and completed interviews. Patients
received information about screening for prostate cancer
(n=13), cardiovascular disease (n=15), colon cancer
(n=14), and osteoporosis (n=19). Eleven patients were
eligible to read two of the screening information sheets.
Patient mean age was 63 years (range 50–84 years; SD
10.82 years). Twenty-eight patients were women, 35
were white, 12 were black, one was Asian, one was
American Indian, and one was multiple races (Table 2).
Perceived Harms
More than two-thirds of patients could not name a harm
of screening when asked "what would you consider to
be a harmful effect of screening?^ Most patients report-
ed having no personal experience with harms or hearing
of harms experienced by others. Many patients stated
that they could more readily name benefits. For exam-
ple, one patient said:
BI can’t really think of any harms. I tend to think of the
benefits because I have friends that have had the
screenings.^ (woman, age 64)
When patients did name harms, many fit into the
domains suggested in the Harris et al. taxonomy of
harms5, including physical, psychological, and financial
harms, and opportunities missed. Of note, however, pa-
tients mentioned psychological harms that extended be-
yond those originally conceptualized in the taxonomy
(e.g., worry or anxiety), including fear, depression, ner-
vousness, paranoia, and feeling out of control.
Patients also mentioned several harms from domains not
enumerated in the original taxonomy. For instance, they
discussed inconvenience or disruption of daily activities as
harmful, particularly as related to colonoscopy preparation.
BAnd then just the prep to go into like a colonoscopy
is… that’s a pretty major undertaking….you can’t eat
and you take all this stuff and then, you know, you
evacuate your system.^ (man, age 51)
Another harm of screening suggested by patients was the
impact on health service use (i.e., either increase or decrease in
use of other services).
BA harmful effect could be that it didn’t really go well
and the person would choose not to do it again…they
would be frightened to think that something’s going to
happen or go wrong again.^ (woman, age 65).
Patients also suggested that screening may negatively affect
an individual’s family (e.g., hassle for family member or
psychological harm to a family member) or society (e.g.,
financial cost to society).
When considering harms, patients typically focused only on
the screening test and not on further actions that might be
necessitated by a positive test result (e.g., follow-up tests,
treatment).
BI mean [bone density testing is] a basic x-ray. It’s an x-
ray test, so there’s no harm in that.^ (woman, age 53).
Table 2 Patient Characteristics
Characteristic % (n)










At least some college 92 (46)
Screening status




Very good 40 (20)
Excellent 14 (7)
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Additionally, many patients minimized the importance
of harms.
BI don’t think that they’re actually harms because the
statistical information is minimal suggesting that there
are any harms.^ (man, age 60).
BI don’t think there are negative things about screen-
ing. I think…possible bad things may happen, but you
don’t know if they would have happened anyway.^
(man, age 61).
Perceived Benefits
Nearly all patients considered screening a necessity for good
health and readily named benefits of screening. A majority
mentioned that knowing is a benefit of screening, and ex-
plained several reasons for this. Some suggested that knowing
Bfor the sake of knowing^ was beneficial, while others
suggested that a screening test might help Bput a name
on something.^
BEven if there's nothing that can be done…just the
knowledge…I'm very interested in my body, and why
shouldn't I be?^ (woman, age 78).
BA lot of times it's a lot easier to deal with stuff when
you can put a name to it or you can know what is going
on.^ (woman, age 50).
Others explained that knowing would give them a
sense of control or an opportunity to research options
and make choices. Patients also suggested that knowing
would give them an opportunity to prepare psychologi-
cally, financially, or interpersonally (e.g., make sure
family is taken care of) for whatever comes next (e.g.,
treatment, ill health, or death).
Another perceived benefit that patients mentioned was
the opportunity for intervention, either with treatment,
monitoring the disease, or behavior change. Patients
seemed to think that most diseases detected early by
screening were treatable.
BWell, I’m sure if they found something, I
would benefit by having them take care of it.
I mean they’d know how to treat it.^ (man, age
76).
If a treatment were not available, patients suggested
that it would be beneficial to monitor the progression
of the disease. Patients valued the opportunity or new
motivation for behavior change, such as improving diet
or physical activity. This benefit was often mentioned
in relation to osteoporosis or cardiovascular disease
screening.
BThis type of screening will help because, again, it kind
of tells me or says, hey, if you keep on the same path
that you’re on right now, this is the trouble that you’re
heading for, but if you can turn it around and start
doing X, Y, Z, then this is going to be a lot better.^
(woman, age 50).
Other perceived benefits of screening included psycholog-
ical benefits (e.g., relief or peace of mind), better prognosis,
better quality of life, the possibility of detecting other health
problems, reducing long-term healthcare costs, reducing the
impact on others (e.g., family, future children), and reducing
the impact on society (e.g., prevention decreases overall
healthcare costs).
BIf it’s found earlier, it’s going to be more easier to
handle financially than if you get to a point that you
have to go to [a hospital] to have heart surgery.^ (man,
age 62).
BIt would help me get my affairs in order and, you
know, see my children. I think that’s always good to
know ahead of time for your family. It would be harder
on me but it would be much better for my family to
know ahead of time.^ (woman, age 53).
Factors Affecting Patients’ Screening Decisions
After reading information sheets about specific screening
tests, patients mentioned many factors, including bene-
fits and harms, that would influence their decisions to
get or avoid the specific screening tests. One of the
most important factors to patients was their physicians’
recommendations. Patients not only suggested that their
physician’s recommendation greatly influenced their de-
cisions to get screened, but some patients also men-
tioned their physician’s recommendation as a motivator
to avoid screening.
BIf the doctor said I don’t think this [PSA test] is the
right thing for you because of your medical history, I
would trust that…by having looked at my medical
history and understanding health problems, I would
take the doctor’s opinion, because that’s what they do.^
(man, age 62).
Patients reported that they assumed that their physi-
cians considered their medical and family history and
guidelines from professional organizations for specific
tests when making recommendations. Many patients
expressed a desire for a discussion with their physicians
1621Sutkowi-Hemstreet et al.: Benefits and harms of overused screening testsJGIM
regarding the benefits and harms of screening rather
than receiving a simple recommendation. Some patients
reported having had discussions with their doctors about
screening, but said that harms were not often part of
those discussions.
Patients mentioned many other factors as both reasons
to get screened or to avoid screening: age, health status,
quality of life, personal or family history of a disease,
race, and past personal experience with screening or
disease. For instance, patients indicated that being youn-
ger was a reason to get screened, and that they might be
less likely to get screened as they got older. They also
indicated that if their quality of life was good, they
might choose to get screened, but might opt out of
screening if their quality of life was poor. Similarly,
patients indicated that they would be motivated to get
screened if they had a personal or family history of
disease, were black and perceived a greater risk for
certain diseases, or had a positive personal experience
with screening. They suggested that they might choose
not to be screened if they had no family history of a
disease, perceived themselves to be at low risk, or had a
negative experience with screening.
Patients also incorporated the following interpersonal fac-
tors into decisions about screening: experience of a friend or
family member with screening or disease, recommendation of
a screening test by a friend or family member, and the impact
of the test results on others (e.g., if the disease were
hereditary).
Finally, patients considered many healthcare factors, such
as the cost of the test, insurance coverage, reputation of the
facility, and mistrust of the medical community. The type of
screening test and disease being tested for also influenced
patients’ decisions about specific screening tests. For example,
patients described the PSA test for prostate cancer as Bjust a
blood test,^ and something they would be willing to do, but
colonoscopy for colon cancer as inconvenient, time-con-
suming, and uncomfortable, and something they might
delay.
Hypothetical Decisions about Screening
After reviewing evidence-based information sheets, the ma-
jority of patients said they would choose to get screened. In
making hypothetical screening decisions, some patients said
they would seek information and opinions and carefully weigh
several factors.
BI seek a lot of information and then would think about
it and…it would probably be something I would dis-
cuss with my wife or other kinds of close friends or
family as well as my doctor. I’d really just go through
an intellectual process, but I think some part of me still
has this emotional thing of the big cancer word.^ (man,
age 51).
Others said screening is Bjust something you are
s u p p o s e d t o d o ^ o r d e p e n d s o n d o c t o r
recommendations.
Some preferred to take time before making decisions.
BI’ll probably go home and what do you call it when
you sit there and stuff goes through your mind and you
work it out over and over. Probably a couple of nights
of that would help me make a decision and maybe
discuss it with my wife.^ (man, age 76).
Patients who had been screened previously and had not
experienced harms often said they would want to get screened
again without much discussion about benefits, harms, or other
factors.
DISCUSSION
Our qualitative study of older adults in a primary care
setting yielded several important findings. First, many
patients could not name screening harms, and most who
named harms focused solely on the harms of the screen-
ing test itself or minimized the harms. Many harms that
patients mentioned aligned with the Harris et al. screen-
ing harms taxonomy (i.e., physical harms, psychological
harms, financial harms, opportunities missed)5, but also
included inconvenience and disruption of daily activities,
increased or decreased health service use, and adverse
effects on family and society. Second, patients could
easily name benefits, and provided a diverse list of
benefits they considered. However, these benefits were
often overestimated or misunderstood. Third, patients
described many other factors (individual, interpersonal,
and healthcare) that they would consider when making
decisions about screening, the most important of which
was the recommendations of their doctor. Fourth, pa-
tients often said they would use heuristics (e.g., rules
of thumb) about screening or suggested they would
ultimately follow the recommendation of the doctor
rather than considering the harms and benefits of
screening.
Our study supports prior conclusions that patients are
enthusiastic about screening14,15, and consider it some-
thing to be done even when the medical community
deems it to have net harm or marginal benefit17,19–21.
Further, our study builds on prior work about patients’
perspectives on potentially harmful tests49,50, demon-
strating a misunderstanding of the benefits and incom-
plete knowledge of the harms of screening tests. For
example, patients considered knowing about disease to
be beneficial. However, patients who are diagnosed
with a disease and are Blabeled^ often experience psy-
chological harms such as distress, depression, and
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anxiety5,51. Furthermore, patients in the study consid-
ered knowing that they had a disease as an opportunity
for action, even though some conditions are not treat-
able. They also considered the possibility of detecting
other health problems as beneficial, although this may
result in additional workup and harms for conditions
that would never have caused any symptoms in a
person’s lifetime. Addressing misconceptions about
such benefits will be important in reducing screening
overuse.
Our study also shows that many patients had diffi-
culty naming the harms of screening or that they
considered only the harms of the screening test itself,
even though harms can happen along the entire screen-
ing cascade, from screening through follow-up tests
and treatment5. One reason for this difficulty could
be that clinicians are not thoroughly discussing possi-
ble harms with their patients52,53. This is supported by
a nationally representative sample showing that pro-
viders discussed the benefits of screening in 90 % of
patient–clinician encounters but discussed the harms in
less than 30 %52. While clinicians may recall the
harms of screening, including unnecessary follow-up
tests and treatment (e.g., tests and treatment for pros-
tate cancer in men with low-grade disease)54, they do
not seem to be sharing this information with patients.
Greater discussion of the harms along the entire
screening cascade will be important for reducing un-
necessary testing, as evidence suggests that when pa-
tients consider the harms or costs of a healthcare
decision as important, they are less likely to choose
to receive the service55. Assisting patients in weighing
benefits and harms may help to ensure that their
screening decisions appropriately take harms into ac-
count56–58.
Finally, our study suggests that patients do not always
weigh the benefits and harms of screening, but instead
sometimes use heuristics, such as Bscreening is what
you are supposed to do^, for screening decisions. Even
after reading information about harms, the majority of
patients wanted screening, and many said they would
rely on heuristics to make these decisions. Given similar
findings in other studies15, interventionists could consid-
er evaluating new heuristics, such as Bnot all screening
tests are the same^ or Bsome screening tests can be
harmful,^ that might prompt patients to appropriately
consider each screening test on its own merit. Further-
more, patients may need assistance in identifying the
best information for decision-making, given the often
conflicting information from family, friends, or the me-
dia, which complicates efforts within the medical com-
munity to reduce overuse.
Overall, we believe that our findings suggest that
overuse of specific screening services is a complex
problem that may require complex strategies to com-
bat. Both clinicians and public health campaigns need
to place more emphasis on clarifying the benefits and
communicating the harms of screening to patients, as
well as countering the unquestioned Bgists^ or general
impressions that all screening is good. Our study fur-
ther suggests appropriate information on harms for
communica t i on by c l in i c i ans and campa igns ,
supplementing that previously mentioned in the Harris
et al. taxonomy5. Screening messages should include
evidence-based information about the benefits of
screening, and should clearly identify the individuals
likely to experience those benefits. Screening messages
should also include information about the full spec-
trum of harms, including possible harms along the
entire screening cascade (from the initial screening test
through diagnosis and treatment)5 and across multiple
domains. Research is needed to determine the type and
number of harms that patients consider important, and
how this may affect their decision-making. Studies will
also need to explore the best approaches for facilitat-
ing appropriate heuristics for screening decisions.
In considering these conclusions, we recognize the
study’s limitations. Study participants were asked to
discuss their experiences with the benefits and harms
of screening. However, because providers sometimes
order tests without discussing them with patients59,
patients in our study did not always remember receiv-
ing screening tests, and thus it is not surprising that
some had difficulty discussing their experiences with
and perceptions of the benefits and harms of screening.
Another limitation is that we asked only about factors
affecting screening decisions in the context of four
specific screening tests. Additional research is needed
to determine whether patients consider these factors,
and possibly others, with regard to other services.
Finally, the generalizability of our sample remains to
be established, as patients in our sample were mostly
well-educated and white. The inclusion of more pa-
tients with lower education levels and minority status
or who are over 85 years old would help us better
understand how well our findings apply to these
populations.
With the growing evidence that some screening tests
may be more harmful than helpful, the medical and
public health communities must determine strategies to
reduce the use of these services. Our study found that
patients were well aware of the benefits of screening,
but may have overestimated those benefits and were not
fully aware of the harms of screening. Additional re-
search is needed to determine the prevalence of these
beliefs, how to provide balanced communication to pa-
tients of screening benefits and harms, and how to
motivate patients to choose against screening when rec-
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ommendations suggest that the harms outweigh the
benefits.
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Table 3 Interview Guide Questions
Topic Questions
Introduction Tell me about a time when you’ve had screening for a health problem.
Potential benefits of screening What kind of benefits, if any, have you experienced from screening?
What would you consider to be a benefit of screening?
Potential harms of screening What kind of harms, if any, have you experience from screening?
What would you consider a harmful effect of screening? (If necessary, probe with screening cascade steps,
such as Bhow about any negative effects from the screening test itself? Diagnosis? Treatment?)
Specific screening (after patient reads
information sheet)
Looking at the information I’ve just given you [information sheet], do you want to get screened?
What information, if any, makes you want to get screened? Avoid getting screened?
How would you go about deciding whether or not to get screened?
What information would you consider when deciding whether or not to get screened?
Whose opinion, if any, would you seek in deciding about screening?
How would you weigh the potential benefits against the potential harms of screening?
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What is prostate cancer? Prostate cancer is an overgrowth of abnormal cells in the prostate, a gland that sits under the urinary bladder. It affects 80 of
every 1,000 men your age. Most prostate cancers will never cause symptoms. Only a few will cause problems with urination and pain. Additionally,
only 4 of every 1,000 men your age who have prostate cancer will die from prostate cancer.
How does prostate cancer screening work? The PSA test is a blood test that helps find prostate cancer. It finds all types of prostate cancer, whether they
would ever cause problems or not.
What are the Benefits of Prostate Cancer Screening? Scientific studies are not completely sure about the benefits of screening. Experts’ best guess is that
finding and treating prostate cancer may lower prostate-related death in 1 of every 1,000 men screened and treated over 10 years (from 4 per 1000 to 3
per 1000).
What are the Harms of Prostate Cancer Screening? The harms of prostate cancer screening are not from the PSA test itself, but from the additional
testing and treatment that follow a positive test.
First, if the PSA test level is high, the next step is a biopsy, which uses small needles to get samples of your prostate. Biopsies result in hospital stays for
urine problems or infection in 50 out of every 1,000 people who have them over 10 years.
Second, if prostate cancer is found, the biopsy doesn’t tell which cancers will cause problems. This leaves many men to wonder and worry. It also means
that most men are treated for their prostate cancer.
Finally, treatment for prostate cancer can harm some men. This includes men with harmless cancers who wouldn’t necessarily need treatment (if doctors
knew who they were). Treatments for prostate cancer include burning with radiation or major surgery. About 260 out of every 1,000 men undergoing
treatment have difficulty with sex because of the treatment and 180 of every 1,000 men have difficulty holding their urine. Surgery also increases the
immediate chances of death in 5 of every 1,000 men treated and increases the chances of heart attacks and blood clots in the legs in 25 of every 1,000
men
The Decision. As you can see, there is a lot to consider before you get a PSA test. So think about what you’ve heard and decide what’s right for you.
Appendix 2 Example Information Sheet
PROSTATE CANCER SCREENING (MEN AGES 65–69)
Here is some information about prostate cancer screening that you might find helpful in your next doctor’s visit.
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